| Full Name | Joshi Medical P.a. |
|---|---|
| Speciality | Family Medicine |
| Location | 417 Oregano Ct, Bear, Delaware |
| Authorized Official Name and Position | Preet D Joshi (PHYSICIAN) |
| Authorized Official Contact | 3029813304 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Joshi Medical P.a. 417 Oregano Ct Bear DE 19701-6019 Ph: () - | Joshi Medical P.a. 417 Oregano Ct Bear DE 19701-6019 Ph: (302) 981-3304 |
| NPI Number | 1548630361 |
|---|---|
| Provider Enumeration Date | 10/06/2015 |
| Last Update Date | 10/06/2015 |
| Medicare PECOS PAC ID | 5890005961 |
|---|---|
| Medicare Enrollment ID | O20151103000434 |
News Archive
Consuming probiotics, so-called 'good bacteria', can reduce body weight and body mass index (BMI) according to a new meta-analysis published in the International Journal of Food Sciences and Nutrition.
Researchers at the California Institute of Technology (Caltech) have engineered a fundamentally new approach to killing cancer cells. The process developed by Niles Pierce, associate professor of applied and computational mathematics and bioengineering at Caltech, and his colleagues uses small RNA molecules that can be programmed to attack only specific cancer cells then, by changing shape, those molecules cause the cancer cells to self destruct.
Scientists at the Wellcome Sanger Institute have discovered that CRISPR/Cas9 gene editing can cause greater genetic damage in cells than was previously thought. These results create safety implications for gene therapies using CRISPR/Cas9 in the future as the unexpected damage could lead to dangerous changes in some cells.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.
The University of Nottingham is to lead a £6.5m research project which aims to make the leap from 2D to 3D in the development of advanced materials and realise the true potential of regenerative medicine and medical devices for the future.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548630361 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | C1-0010514 (Delaware) | Primary |
| Provider Name | Preet D Joshi |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1538391347 PECOS PAC ID: 0446494678 Enrollment ID: I20130910000259 |
News Archive
Consuming probiotics, so-called 'good bacteria', can reduce body weight and body mass index (BMI) according to a new meta-analysis published in the International Journal of Food Sciences and Nutrition.
Researchers at the California Institute of Technology (Caltech) have engineered a fundamentally new approach to killing cancer cells. The process developed by Niles Pierce, associate professor of applied and computational mathematics and bioengineering at Caltech, and his colleagues uses small RNA molecules that can be programmed to attack only specific cancer cells then, by changing shape, those molecules cause the cancer cells to self destruct.
Scientists at the Wellcome Sanger Institute have discovered that CRISPR/Cas9 gene editing can cause greater genetic damage in cells than was previously thought. These results create safety implications for gene therapies using CRISPR/Cas9 in the future as the unexpected damage could lead to dangerous changes in some cells.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.
The University of Nottingham is to lead a £6.5m research project which aims to make the leap from 2D to 3D in the development of advanced materials and realise the true potential of regenerative medicine and medical devices for the future.
› Verified 3 days ago
News Archive
Consuming probiotics, so-called 'good bacteria', can reduce body weight and body mass index (BMI) according to a new meta-analysis published in the International Journal of Food Sciences and Nutrition.
Researchers at the California Institute of Technology (Caltech) have engineered a fundamentally new approach to killing cancer cells. The process developed by Niles Pierce, associate professor of applied and computational mathematics and bioengineering at Caltech, and his colleagues uses small RNA molecules that can be programmed to attack only specific cancer cells then, by changing shape, those molecules cause the cancer cells to self destruct.
Scientists at the Wellcome Sanger Institute have discovered that CRISPR/Cas9 gene editing can cause greater genetic damage in cells than was previously thought. These results create safety implications for gene therapies using CRISPR/Cas9 in the future as the unexpected damage could lead to dangerous changes in some cells.
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.
The University of Nottingham is to lead a £6.5m research project which aims to make the leap from 2D to 3D in the development of advanced materials and realise the true potential of regenerative medicine and medical devices for the future.
› Verified 3 days ago
Greenbrook Tms Newark, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 121 Becks Woods Dr Ste 202, Bear, DE 19701 Phone: 855-755-4867 | |
Reliance Healthcare, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1993 Pulaski Hwy, Bear, DE 19701 Phone: 302-838-3100 | |
The Life Health Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4050 Wrangle Hill Rd, Bear, DE 19701 Phone: 302-552-3574 Fax: 302-552-3561 | |
United Medical Accountable Care Organization, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 161 Becks Woods Dr, Bear, DE 19701 Phone: 302-451-5600 Fax: 866-319-6725 | |
United Medical Clinic Of De, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 121 Becks Woods Dr Ste 100, Bear, DE 19701 Phone: 302-261-5600 Fax: 302-836-4302 | |
Home Physician Network Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2443 Mccoy Rd, Bear, DE 19701 Phone: 302-832-5099 |